title: Decreased expression of BTG3 was linked to carcinogenesis, aggressiveness, and prognosis of ovarian carcinoma.
abstract: B-cell translocation gene 3 (BTG3) is a member of the BTG family which inhibits cell proliferation, metastasis, and angiogenesis, and also regulates cell-cycle progression and differentiation in a variety of cell types. However, there is no study to analyze BTG3 expression in epithelial ovarian carcinoma (EOC). Here, we investigated the expression of BTG3 in EOC carcinogenesis and subsequent progression. BTG3 mRNA expression was detected by real-time RT-PCR in ovarian benign and malignant tumors. The expression of BTG3 protein was examined by immunohistochemistry on tissue microarrays containing ovarian normal tissue, benign and borderline epithelial ovarian tumors, and EOCs. Relationships of BTG3 with both EOC clinicopathology and prognosis were analyzed statistically. The expression of BTG3 protein was also evaluated in ovarian normal tissue, benign tumors, and EOCs by western blot. The BTG3 mRNA expression level was higher in ovarian normal tissue and benign tumors than that in borderline, primary, and metastatic carcinoma (p < 0.05), and was negatively correlated with dedifferentiation and FIGO staging of EOC (p < 0.05). Using western blot, BTG3 protein was found lower in EOCs compared to the normal and benign tumors (p < 0.05), and poorly differentiated EOCs showed lower BTG3 expression than well-differentiated and moderately differentiated EOCs (p < 0.05). Immunohistochemically, BTG3 protein expression was statistically lower in EOCs than normal tissue and benign tumors (p < 0.05). EOC patients with low BTG3 protein expression showed a higher incidence of metastasis (p = 0.020), poor differentiation (p = 0.030), and shorter disease-free time and overall survival time (p < 0.05). By using Cox's proportional hazard model, BTG3 protein expression and FIGO staging were independent prognostic factors for both disease-free time and overall survival time of EOCs (p < 0.05). It was suggested that down-regulated BTG3 expression might play roles in the pathogenesis and aggressiveness of EOC. BTG3 protein expression may be considered as a good marker to indicate the favorable prognosis of EOCs.
authors: Department of Gynecology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
authors: Boya
authors: B
authors: Deng
authors: Yang
authors: Y
authors: Zhao
authors: Wenfeng
authors: W
authors: Gou
authors: Shuo
authors: S
authors: Chen
authors: Xiaoyun
authors: X
authors: Mao
authors: Yasuo
authors: Y
authors: Takano
authors: Huachuan
authors: H
authors: Zheng
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D018394:CA-125 Antigen / Q000097:blood; D063646:Carcinogenesis / Q000378:metabolism*; D018797:Cell Cycle Proteins; D005260:Female; D015870:Gene Expression; D006801:Humans; D053208:Kaplan-Meier Estimate; D008565:Membrane Proteins / Q000097:blood; D008875:Middle Aged; D015999:Multivariate Analysis; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D011506:Proteins / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D046888:Tissue Array Analysis; D055815:Young Adult
chemical_list: C424522:BTG3 protein, human; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018797:Cell Cycle Proteins; C451759:MUC16 protein, human; D008565:Membrane Proteins; D011506:Proteins; D012333:RNA, Messenger
references: Mol Oncol. 2011 Feb;5(1):77-92
references: 21169070
references: Clin Obstet Gynecol. 2012 Mar;55(1):3-23
references: 22343225
references: Eur J Cancer Prev. 2013 Jan;22(1):59-67
references: 22694826
references: Semin Surg Oncol. 1994 Jan-Feb;10(1):31-46
references: 8115784
references: J Cell Sci. 2006 Feb 15;119(Pt 4):646-58
references: 16434477
references: N Engl J Med. 1983 Oct 13;309(15):883-7
references: 6310399
references: Oncogene. 2012 Jul 5;31(27):3287-97
references: 22020331
references: Leukemia. 1997 Mar;11(3):370-5
references: 9067576
references: Oncogene. 2004 Aug 26;23(39):6630-8
references: 15235587
references: Cancer Sci. 2009 Feb;100(2):225-32
references: 19068083
references: Cancer. 2010 Jan 1;116(1):66-76
references: 19885928
references: Obstet Gynecol. 2002 Jul;100(1):59-64
references: 12100804
references: Br J Cancer. 2001 Mar 23;84(6):754-9
references: 11259088
references: Jpn J Cancer Res. 2001 Jun;92(6):592-6
references: 11429045
references: Int J Gynecol Cancer. 2012 May;22(4):586-92
references: 22266931
references: BMC Cancer. 2010 Jun 16;10:296
references: 20553615
references: PLoS One. 2012;7(12):e51331
references: 23236473
references: Eur J Biochem. 2002 Jul;269(14):3596-604
references: 12135500
references: Gene Expr. 2008;14(3):173-82
references: 18590053
references: Mod Pathol. 2004 Sep;17(9):1141-9
references: 15167936
references: EMBO J. 2007 Sep 5;26(17):3968-80
references: 17690688
references: J Cell Physiol. 2010 Jan;222(1):66-72
references: 19746446
references: Gynecol Oncol. 2010 Dec;119(3):462-8
references: 20850174
references: Carcinogenesis. 2009 Apr;30(4):662-70
references: 19221000
references: J Biol Chem. 2009 Apr 17;284(16):10593-600
references: 19234306
references: CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
references: 17237035
references: Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92
references: 17161157